<DOC>
	<DOCNO>NCT01190449</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , ofatumumab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . PURPOSE : This randomized phase II trial study ofatumumab see well work treat patient previously untreated stage II , stage III , stage IV follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Ofatumumab Treating Patients With Previously Untreated Stage II , Stage III , Stage IV Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine response rate patient previously untreated CD20-positive bulky stage II , stage III IV follicular non-Hodgkin lymphoma ( NHL ) treat lower- high-dose ofatumumab . Secondary - To determine progression-free survival ( PFS ) patient treat regimen . - To determine toxicity profile regimens patient . - To establish whether therapeutic effect single-agent ofatumumab sufficiently promise warrant evaluation subsequent randomize , ofatumumab-based , biologic doublet trial . - To evaluate two ofatumumab dos independent comparison response , PFS , toxicity historical control previously untreated patient follicular NHL . - To prospectively validate FLIPI2 prognostic index low- intermediate-risk patient compare low- intermediate-risk stratified patient standard FLIPI score determine reliable indicator response PFS . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive high-dose ofatumumab IV 2-8 hour day 1 , 8 , 15 , 22 monthly month 3-9 . - Arm II : Patients receive low dose ofatumumab IV 2-8 hour day 1 , 8 , 15 , 22 monthly month 3-9 . In arm , treatment continue absence disease progression unacceptable toxicity . Patients may undergo blood bone marrow sample collection correlative study . After completion study therapy , patient follow every 4 month 2 year every 6 month 8 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular nonHodgkin lymphoma ( NHL ) meet 1 follow criterion : Bulky ( i.e. , single mass ≥ 7cm unidimensional measurement ) stage II disease Stage III IV disease WHO grade 1 , 2 , 3a disease Bone marrow biopsy allow provide submit conjunction nodal biopsies No fineneedle aspirate diagnosis Tumor tissue must express CD20positive antigen flow cytometry IHC At least 1 site measurable disease &gt; 1 cm diameter ≥ 1 dimension present either physical exam image study Nonmeasurable disease alone allow , include follow : Bone lesion ( lesion present note ) Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Bone marrow ( involvement NHL note ) Low intermediaterisk disease Follicular Lymphoma International Prognostic Index ( FLIPI ) FLIPI score meeting 1 2 follow risk factor : Age &gt; 60 year Involvement &gt; 4 nodal site Stage IIIIV disease Hemoglobin &lt; 12.0 g/dL LDH normal Risk determine follow : Low Risk : 01 risk factor Intermediate Risk : 2 risk factor Poor Risk : ≥ 3 risk factor No know CNS involvement PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,000/μL Platelet count ≥ 75,000/μL Creatinine clearance ≥ 30 mL/min Bilirubin ≤ 2 time upper limit normal ( unless secondary Gilbert syndrome hepatic involvement NHL ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Patients HIV infection allow provide follow criterion meet : No evidence coinfection hepatitis B C CD4+ cell count ≥ 400/mm³ No evidence resistant strain HIV HIV viral load &lt; 10,000 copy HIV RNA/mL antiHIV therapy OR HIV viral load &lt; 50 copy antiHIV therapy No history AIDSdefining condition No evidence active hepatitis B ( HBV ) C ( HCV ) infection ( i.e. , positive serology antiHBc antiHCV antibody ) HBV seropositivity allow ( HBsAg+ ) provide closely monitored evidence active HBV infection HBV DNA test After complete treatment , HBsAg + patient must monitor HBV DNA test every 2 month 6 month posttreatment , continue lamivudine ( require ) PRIOR CONCURRENT THERAPY : No prior chemotherapy immunotherapy ( e.g. , monoclonal antibodybased therapy ) NHL Prior involvedfield radiation therapy allow More 2 week since prior corticosteroid except maintenance therapy nonmalignant disease No concurrent dexamethasone steroid antiemetics No live virus vaccination within 6 week prior study entry No concurrent zidvoudine stavudine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
</DOC>